SALARIUS PHARMACEUTICALS INC (SLRX)

Company Profile

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. The company is headquartered in Houston, Texas and currently employs 12 full-time employees. The company went IPO on 2015-01-29. The firm is focused on developing effective treatments for cancers with unmet medical needs. The company is developing treatments for cancers caused by dysregulated gene expression. The Company’s product portfolio includes seclidemstat, which is being studied as a potential treatment for pediatric cancers, sarcomas and other cancers with limited treatment options. The firm's pipeline consists of two primary compounds: SP-3164, a small-molecule protein degrader, and seclidemstat (SP-2577), a small-molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening.

Company Info

SALARIUS PHARMACEUTICALS INC

2450 Holcombe Blvd Ste J-608

Houston TEXAS 77021

P: 13467720346

CEO: David J. Arthur

Employees: 12

Website: https://salariuspharma.com/